Media

Taiwan Pavilion debuts at BioJapan 2026, showcasing the CDMO and regenerative medicine capabilities of 17 elite institutions, including GWO XI.

Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) announced that its investigational stem cell medicine GXNPC1®, developed for chronic stroke-related disability, has officially received approval from the Taiwan Food and Drug Administration (TFDA) to initiate a Phase III clinical trial, marking a significant advancement in the clinical development of GXNPC1® and Gwo Xi’s efforts to address the unmet medical needs of patients living with long-term post-stroke disability. Built on regenerative medicine technology, GXNPC1® is intended to address persistent neurological imp

四樣台灣的生醫科技解決人類一生中可能遇到的潛在健康問題，從研發到實驗跟你說故事